BMS-8

SKU: orb1305168

Description

BMS-8 is a small molecule PD-1/PD-L1 interaction inhibitor with an IC50 of 7.2 µM. It functions by binding to PD-L1 and promoting its homodimerization. This mechanism supports its application in cancer immunotherapy research, including in vitro assays to study immune checkpoint blockade.

Research Area

Cell Biology, Immunology & Inflammation

Key Properties

• CAS Number: 1675201-90-7
• MW: 494.42
• Purity: 99.06% (May vary between batches)
• Formula: C₂₇H₂₈BrNO₃
• SMILES: Cc1c(COc2ccc(CN3CCCCC3C(O)=O)cc2Br)cccc1-c1ccccc1
• Target: PD-1/PD-L1
• Solubility: DMSO:15.31 mg/mL (30.97 mM)

Bioactivity

• Target IC50:
  PD-1/PD-L1:7.2 μM
• In Vitro:
  BMS-8 demonstrates a more stable binding affinity for one PD-L1 monomer compared to another, with its ability to induce PD-L1 dimerization further enhanced by non-polar interactions involving Ile54, Tyr56, Met115, Ala121, and Tyr123 on each monomer, in addition to the involvement of water-mediated bridges at ALys124.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

PPI, PD-L1, PDL1, inhibit, PD-1/PD-L1, PD1/PDL1, PD-1, PD1, Inhibitor, BMS 8, BMS8, BMS-8

Compound Identifiers

PubChem CID

117941742